Effectiveness of cognitive-behavioral therapy for smokers with histories of alcohol dependence and depression.

Patten, Christi A.; Martin, John E.; Myers, Mark G.; Calfas, Karen J.; Williams, Carl D.

doi:10.15288/jsa.1998.59.327

Cited by 76 publications

(47 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies suggested that the additional contact time, rather than the specific mood management skills, benefited past MDD smokers. However, in a study of smokers with a history of both MDD and alcohol dependence, a group cognitive-behavioral mood management program was associated with significantly higher rates of smoking abstinence compared with a behavioral skills control group (Patten, Martin, Myers, Calfas, & Williams, 1998).…”

Section: Introductionmentioning

confidence: 92%

Bupropion and cognitive-behavioral treatment for depression in smoking cessation

Brown

Niaura

Lloyd-Richardson

et al. 2007

Nicotine & Tobacco Res.

View full text Add to dashboard Cite

This study is a randomized, double-blind, placebo-controlled clinical trial examining the effects of an intensive cognitive-behavioral mood management treatment (CBTD) and of bupropion, both singularly and in combination, on smoking cessation in adult smokers. As an extension of our previous work, we planned to examine the synergistic effects of CBTD and bupropion on smoking cessation outcomes in general and among smokers with depression vulnerability factors. Participants were 524 smokers (47.5% female, M age =44.27 years) who were randomized to one of four 12-week treatments: (a) standard, cognitive-behavioral smoking cessation treatment (ST) plus bupropion (BUP), (b) ST plus placebo (PLAC), (c) standard cessation treatment combined with cognitivebehavioral treatment for depression (CBTD) plus BUP, and (d) CBTD plus PLAC. Follow-up assessments were conducted 2, 6, and 12 months after treatment, and self-reported abstinence was verified biochemically. Consistent with previous studies, bupropion, in comparison with placebo, resulted in better smoking outcomes in both intensive group treatments. Adding CBTD to standard intensive group treatment did not result in improved smoking cessation outcomes. In addition, neither CBTD nor bupropion, either alone or in combination, was differentially effective for smokers with single-past-episode major depressive disorder (MDD), recurrent MDD, or elevated depressive symptoms. However, findings with regard to recurrent MDD and elevated depressive symptoms should be interpreted with caution given the low rate of recurrent MDD and the low level of depressive symptoms in our sample. An a priori test of treatment effects in smokers with these depression vulnerability factors is warranted in future clinical trials.

show abstract

Section: Introductionmentioning

confidence: 92%

Bupropion and cognitive-behavioral treatment for depression in smoking cessation

Brown

Niaura

Lloyd-Richardson

et al. 2007

Nicotine & Tobacco Res.

View full text Add to dashboard Cite

show abstract

“…Most research in this area has focused on tobacco use. Several trials have examined the effects of cognitive behavior therapy in smokers with a lifetime history of major depression [88][89][90][91]. Most of these studies show positive results, although most of the sample sizes are small and more research in this area is needed.…”

Section: Does Treatment Of Depression Affect Survival?mentioning

confidence: 99%

Increased mortality in depressive disorders: A review

Cuijpers

Schoevers²

2004

Curr Psychiatry Rep

139

View full text Add to dashboard Cite

“…Relative strengths of CBT as a behavioral platform includes its established efficacy (DeRubeis and Crits-Christoph, 1998; Irvin et al, 1999;Miller and Wilbourne, 2002c;Morgenstern and Longabaugh, 2000), its durability beyond the active treatment period (Carroll et al, 2000;Carroll et al, 1994b;Rawson et al, 2002) as well as emerging evidence that it may have a complementary role with some pharmacotherapies (Anton et al, 1999;Carroll et al, 2004;Carroll et al, 1998a;Hall et al, 2002;Heinala et al, 2001;O'Malley et al, 1996;O'Malley et al, 2003). CBT's efficacy across a range of different psychiatric disorders (DeRubeis and Crits-Christoph, 1998) also makes this approach attractive for trials targeting populations with dual disorders (Brown et al, 1997;George et al, 2000;Mason et al, 1999;McDowell et al, 2000;Nunes et al, 1998;Patten et al, 1998;Schmitz et al, 2001a). Relative weaknesses of CBT are that comparatively extensive staff training is needed to learn to implement CBT effectively (Morgenstern et al, 2001;Sholomskas et al, 2002).…”

Section: Cognitive-behavioral Approachesmentioning

confidence: 99%

Choosing a behavioral therapy platform for pharmacotherapy of substance users

Carroll

Kosten

Rounsaville

2004

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Behavioral therapy platforms have become virtual requirements in pharmacotherapy trials due to their utility in reducing noise variability, preventing differential medication adherence and protocol attrition, enhancing statistical power and addressing ethical issues in placebo-controlled trials. Selecting an appropriate behavioral platform for a particular trial requires study-specific tailoring, taking into account both the stage of development of the medication being evaluated, as well as the specific strengths and weaknesses of a broad array of available empirically supported behavioral therapies and the range of their possible targets (e.g., enhancing medication adherence, preventing attrition, addressing co-morbid problems, fostering abstinence, and targeting specific weaknesses of the pharmacologic agent). Choosing a suitable behavioral platform also requires consideration of the characteristics of the population to be treated, stage of scientific knowledge regarding the medication's effects, appropriate balance of internal and external validity, and consideration of potential ceiling effects. Available manualized behavioral treatments are reviewed, noting their strengths and limitations as behavioral therapy platforms for pharmacotherapy trials and as potential concomitant therapies in clinical practice.

show abstract

Effectiveness of cognitive-behavioral therapy for smokers with histories of alcohol dependence and depression.

Cited by 76 publications

References 23 publications

Bupropion and cognitive-behavioral treatment for depression in smoking cessation

Bupropion and cognitive-behavioral treatment for depression in smoking cessation

Increased mortality in depressive disorders: A review

Choosing a behavioral therapy platform for pharmacotherapy of substance users

Contact Info

Product

Resources

About